EVM
PTLA

Eaton Vance Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Eaton Vance Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-106,920
Closed -$2.87M – 1332
2019
Q3 		$2.87M Buy
+106,920
New +$3M 0.01% 727

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Eaton Vance Management's PTLA Position: Q4 2019 in Review

Eaton Vance Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2019, closing a stake of 106,920 shares — an estimated $2.87M sold.

Eaton Vance Management first reported a position in PTLA in Q3 2019 and held it in 1 quarter. The position peaked at $2.87M in Q3 2019. 224 funds tracked by Wall St. Rank hold PTLA as of Q4 2019.

  • Eaton Vance Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Eaton Vance Management sold 106,920 Portola Pharmaceuticals, Inc. shares in Q4 2019, an estimated $2.87M.
  • Eaton Vance Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2019 and held it in 1 quarter.
  • Eaton Vance Management's Portola Pharmaceuticals, Inc. position peaked at $2.87M in Q3 2019.
  • 224 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2019.

Based on Eaton Vance Management's 13F filing for Q4 2019, filed 11 Feb 2020.